Press Releases
iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H., Nov. 14, 2023 — iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, President and Chief Executive Officer and Eric Lonnqvist, Chief Financial Officer, will participate…
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
NASHUA, N.H. – November 13, 2023 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September…
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
NASHUA, NH., October 30, 2023 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that it will release financial results for the third quarter ended September 30,…
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
Xoft’s eBx System can now be offered to more clinics and cancer patients world-wide through Elekta’s extensive sales channels NASHUA, N.H., October 23, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions announced today that Elekta (EKTA-B.ST), the world leader in brachytherapy solutions,…
Health Canada Grants Device License for iCAD’s ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
NASHUA, N.H., August 16, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada has issued a device license for ProFound Risk version 2.0, the latest version of iCAD’s personalized 1-2 year breast cancer risk assessment solution. …
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June…
iCAD and Google Health Expand Integration of Google’s AI Technology with iCAD’s ProFound Breast Health Suite for 2D Mammography for Use as Independent Reader
Worldwide commercialization agreement offers potential to ease radiologist workload and reduce healthcare disparities for women NASHUA, N.H., August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it signed an amendment to its development and commercialization agreement with…
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
NASHUA, N.H., July 31, 2023 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023. …
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
Agreement positions iCAD as Radiology Partners’ breast AI provider, expanding potential for iCAD’s technology to reach millions of women in the U.S. NASHUA, N.H., July 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a…
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD’s Breast AI Suite helps her detect the breast cancers radiologists fear most NASHUA, N.H., July 12, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound…